<DOC>
	<DOCNO>NCT02698293</DOCNO>
	<brief_summary>This phase I dose escalation study photodynamic therapy ( PDT ) treatment patient pre-malignant tumor superficial microinvasive disease anal canal and/or perianal skin . All subject ( maximum 12 ) give photosensitizer Gliolan orally follow administration red light ( 629-635 nm ) tumor laser . The dose Gliolan 40 mg/kg administer approximately 4-6 hour light administration . There two level light dose : 50 100 J/cm2 , 3-6 patient . Patients observe 30 day development DLT . Patients follow 24 month additional toxicity efficacy data collection .</brief_summary>
	<brief_title>A Phase I Study Photodynamic Therapy ( PDT ) High-grade Anal Dysplasia Microinvasive Anal Cancer</brief_title>
	<detailed_description />
	<mesh_term>Anus Neoplasms</mesh_term>
	<criteria>A histological cytological diagnosis highgrade dysplasia carcinoma insitu , within past 4 month . Premalignant lesion contain focal microinvasion eligible : Surgery clinically mandate . Subjects medical condition preclude surgery . Subjects whose lesion completely resect base size location , significant functional morbidity would anticipate surgery . Patients refuse surgery . The justification inclusion patient microinvasive disease base report demonstrate ability photodynamic therapy successfully treat dysplasia T1 squamous cell carcinoma anal canal ( 22 ) . ECOG performance status 01 . 18 year age old . Study subject capable provide informed consent . Study subject lesion invasive squamous cell carcinoma anal cavity clinically appreciable . Clinically occult microinvasive squamous cell carcinoma anal cavity focal . Study subject pregnant lactating . Study subject platelet count le 100,000/cubic mm . Study subject elevate aspartate aminotransferase ( AST ) , alanine aminotransferase ( ALT ) , alkaline phosphatase , total bilirubin level &gt; 2X normal history chronic liver disease cirrhosis liver . Significant cardiovascular history would put study subject risk hypotension may occur Gliolan Study subject porphyria hypersensitivity porphyrin . Study subject abnormal baseline creatinine level diagnose kidney disease . Study subject medical history immune suppression . This include patient past transplantation require ongoing immunosuppressive medication . Patients HIV infection eligible provide highly active antiretroviral therapy recent CD4 count &gt; 200</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2016</verification_date>
</DOC>